Consumers experiencing a gap in their Medicare Part D prescription drug coverage were more likely to forgo diabetes medications than those who had supplemental drug benefits. Business Week reports: "Medicare's so-called 'doughnut hole' could be forcing many American seniors to skip their diabetes medications, a new study suggests." The doughnut hole occurs because Medicare covers prescription drug costs up to a certain amount and then consumers must pick up the tab until they've hit another spending threshold. The study was based on 2006 data, "when Part D coverage included up to $2, 250 in total drug costs paid by both the patient and plan. ... The plan started paying again when people reached $3, 600 in total out-of-pocket drug expenses for the year.
On 11 January 1922 insulin was first used successfully in the treatment of diabetes. Insulin was discovered by Sir Frederick G Banting (pictured), Charles H Best and JJR Macleod at the University of Toronto in 1921 and it was subsequently purified by James B Collip. Before 1921, it was exceptional for people with Type 1 diabetes to live more than a year or two. One of the twentieth century's greatest medical discoveries, it remains the only effective treatment for people with Type 1 diabetes today. First successful use On 11 January 1922, Leonard Thompson, a 14-year-old boy with diabetes, who lay dying at the Toronto General Hospital, was given the first injection of insulin.
A new study claims that some older people with mild memory-loss are three times more likely to develop dementia if they also have diabetes. The research, by Alzheimer's Research Trust scientists at King's College London, published in the British Journal of Psychiatry, investigated the connection between mild cognitive impairment (MCI) in older people and dementia. Results The scientists followed 61 people aged 65 or over who had MCI over a period of four years. 16 (26 per cent) of the participants had diabetes. Results show that after four years, 19 (31 per cent) developed dementia, two (3 per cent) reverted to normal cognitive levels, and 40 (59 per cent) remained stable.
In a year that will be remembered for swine flu and health care reform, the American Diabetes Association today released a year-in-review list on another topic that received major headlines in 2009: diabetes. The list focuses on achievements made in 2009 to stop diabetes. "Nearly 24 million Americans have diabetes and the numbers are not expected to decrease any time soon, " commented Larry Hausner, CEO, American Diabetes Association. "But even though the seriousness and scope of diabetes is daunting, the American Diabetes Association made many important strides in 2009 to help stem the tide of this deadly disease." Below are nine achievements in diabetes in 2009: 1) Reforming Health Care The Association took a lead role to ensure that pending federal health care reform legislation meets the needs of people with, and at risk for, diabetes.
JDRF Forms Partnership With Animas To Develop First-Generation Automated System For Managing Type 1 Diabetes
The Juvenile Diabetes Research Foundation announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease -- the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels. Animas, a Johnson & Johnson company, is a leading manufacturer and distributor of insulin delivery and glucose management systems. JDRF is a global leader in research leading to better treatments and cures for type 1 diabetes.
Medical Care Technologies Inc. (OTCBB: MDCE) today announced that it has commenced trials to include Continuous Glucose Monitoring (CGM) to its current Tele-Health™ Suite. Management believes that by adding this function to its Tele-Health™ technology, users will be able to monitor and better control their diabetes while reducing costs. The Tele-Health™ Suite is a software that enables continuous interaction between the patient and the healthcare professionals for a more efficient and effective way of treating, supporting, managing and monitoring wellness. With this application we will focus on patients with diabetes. This unique solution will every day instruct patients to measure their blood glucose readings, as required to their long term condition.
Diabetes mellitus is one of the most common chronic disease of the world and the prevalence of diabetes mellitus is over 10% in Taiwan. Gastroparesis is reported in 5% to 12% of diabetic patients. Superior mesenteric artery (SMA) syndrome is an uncommon disease resulting compression of the third portion of the duodenum from the superior mesenteric artery. However, SMA syndrome can cause the same symptoms as diabetic gastroparesis. A research team, led by Dr. Wen-Ming Wang from Kaohsiung Medical University Hospital reported a rare etiology of superior mesenteric artery syndrome. Their study was published on December 21, 2009 in the World Journal of Gastroenterology.
A new understanding and possible treatment for Type 2 diabetes could be on its way after one of the largest genetic studies to date discovered nine new genes linked to the condition. The genes and blood glucose levels of over 120, 000 volunteers were studied by scientists from 174 research centres across the world. A set of genes that control the body's response to glucose in the blood was identified. "An incredibly important finding" "This is an incredibly important finding, " said Jim Wilson, a geneticist from Edinburgh University involved in the study. "The discovery of these new genes influencing blood sugar levels is the first step on the important journey to developing new therapies for diabetes.
PSivida CEO To Discuss Ocular Drug Delivery In Diabetic Retinopathy At 6th Annual Diabetes Conference January 22 In London
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22. In his presentation Dr. Ashton will describe the barriers to clinically effective therapies in diabetic retinopathy and the difficulty of getting drugs to the back of the eye, where most diabetic eye disease manifests itself.
In recent years, there has been a large increase in the prevalence of overweight and obese women of childbearing age, with approximately 51% of non-pregnant women ages 20 to 39 being classified as overweight or obese. A new article published in the journal Nursing for Women's Health finds that obesity in pregnant women is associated with pregnancy complications, birth defects, as well as a greater risk of childhood and adult obesity in infants born to obese mothers. Merrie Rebecca Walters, RN, and Julie Smith Taylor, PhD, RNC, WHNP-BC, reviewed the potential consequences of maternal obesity. Results show that obese women are more likely to have an infant with a neural tube defect, heart defects, or multiple anomalies than women with a normal BMI.